Status:
UNKNOWN
Diagnostic and Prognostic Utility of Pentraxin 3 in Patients With Acute STEMI Undergoing Primary PCI
Lead Sponsor:
Assiut University
Conditions:
Myocardial Infarction
Eligibility:
All Genders
Phase:
NA
Brief Summary
A number of inflammatory markers have been recognized, among which the acute phase reactant C-reactive protein showed a positive correlation with the risk of coronary artery disease in both healthy in...
Detailed Description
A number of inflammatory markers have been recognized, among which the acute phase reactant C-reactive protein showed a positive correlation with the risk of coronary artery disease in both healthy in...
Eligibility Criteria
Inclusion
- 1\. Patients presenting to our CCU with acute myocardial infarction (STEMI) undergoing PPCI: chest pain \> 30 minutes and ST segment elevation in more than one lead, include the definition of MI with a reference: Third universal definition of MI.
Exclusion
- Patients complicated with an infectious disease on admission, active systemic inflammatory disease or chronic inflammatory disease(systemic lupus ,rheumatoid arthritis ,etc).
- Immune system disease or glucocorticoid therapy.
- Patients with history of cancer
- Patients of chronic kidney disease
- Patients on regular treatments with statins
- Patients of valvular heart disease, atrial fibrillation (positive relation was proved by previous studies), heart failure and/or cardiogenic shock.
- Patients underwent previous elective pci or previous CABG.
Key Trial Info
Start Date :
November 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2020
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03476252
Start Date
November 1 2018
End Date
November 1 2020
Last Update
March 27 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.